Navigation Links
Little known pregnancy disease, Hyperemesis Gravidarum, receives awareness with a $20,000 donation from the H.E.R. Foundation to begin Genome Research at UCLA
Date:7/9/2012

LEESBURG, Va., July 9, 2012 /PRNewswire-iReach/ -- The HER Foundation (Hyperemesis Education & Research), the voice of HG, presented $20,000 to UCLA's medical research department and the Hyperemesis Gravidarum Genome Project. Hyperemesis Gravidarum (HG) is a debilitating and potentially life-threatening pregnancy disease marked by rapid weight loss, malnutrition, and dehydration due to unrelenting nausea and/or vomiting with potential adverse consequences for the newborn(s). HG is the second leading cause of hospitalization during pregnancy, yet few dollars are granted for research.

The research, conducted by lead researcher Dr. Marlena Fejzo, will focus on identifying the gene associated with Hyperemesis Gravidarum (HG), and how the effects of this disease, brought on by pregnancy, affect the mother and child.  Dr. Fejzo states, "The latest award of $20,000 from the HER Foundation will enable us to use an exciting novel technology to identify the gene(s) and corresponding biological pathways related to HG in HG-families." 

Kimber MacGibbon, co-founder of the HER Foundation says, "We are very excited to support this important genetic study that will give us greater understanding of Hyperemesis Gravidarum, as well as the opportunity to identify mothers at risk for HG so they can receive proactive care. Ultimately, this study will improve the care of those with HG and disprove the erroneous beliefs about the cause of HG."

The national cost of treating HG in the inpatient setting increased 50% from $167 million in 2000 to $250 million in 2009. Recent studies show HG is associated with low birth weight, intrauterine growth restriction, preterm delivery, and fetal and neonatal death.  Elective pregnancy termination in a large cohort of women with Hyperemesis Gravidarum have also been shown in recent studies. Recurrence rates are greatly underestimated because HG is often not diagnosed, not properly recorded, and/or not treated by hospital visits.

Dr. Fejzo added, "This is a very exciting time in the world of HG research, as I truly believe we are on the verge of discovering once and for all, the cause of this devastating pregnancy disease, that will bring us one step closer to a cure." Ann Marie King, co-founder of the HER Foundation said, "HG turns a woman's dream of a healthy pregnancy into a nightmare and women around the globe are begging for more research on the disease. We hear from women around the world looking for help and understanding, we are hoping this is the first step to getting answers for so many women who simply want to bring a child into the world."

The HER Foundation is the world's leading non-profit organization dedicated to the education, research and awareness of Hyperemesis Gravidarum. Just in the past two years the HER Foundation has donated a total of $45,000 to HG research at both USC and UCLA.  This research has aided medical professionals to prove that HG is a genetic condition. To learn more about Hyperemesis Gravadarum and The HER Foundation, visit www.HelpHER.org or www.facebook.com/HERFoundation.

 

Media contacts:

Ann Marie King - HER Foundation

703-399-1272

annmarie@helpher.org

                                                                       

Enrique Rivero – UCLA Media Relations

(310) 794-2273 (310) 794-0777

erivero@mednet.ucla.edu

Media Contact: Ann Marie King The HER Foundation, 7033991272, annmarie@helpher.org News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE The HER Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Medzilla.com Special Report: Unemployed Can Breathe a Little Freer After Supreme Court's Affordable Care Act Ruling
2. Study dusts sugar coating off little-known regulation in cells
3. Eczema in Babies Due to Stress in Pregnancy
4. Morning Sickness or NVP: National Survey of Nurse Practitioners Points to Underreporting of Common Condition in Pregnancy
5. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
6. Lupin Receives FDA Approval for Generic LYRICA(R)
7. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
8. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
9. Nourish the World! Terra Biotech Receives Thanks and Praise After First Shipment of 10,000 Servings of Nectr Core Vitamin Powder to Orphans in Ghana, Africa
10. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
11. Exotic Automation & Supply Receives Ford’s 2011 World Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... PA (PRWEB) , ... January 20, 2017 , ... The ... transforming healthcare treatment options for patients. Vironika, a spin out from The Wistar Institute, ... both taking lab space at 3624 Market Street. , Vironika is developing a ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
Breaking Biology Technology:
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):